Taken together, our preclinical data suggest that the combination strategy of trametinib plus anlotinib synergistically induces antitumor activity in KRAS-mutant NSCLC, potentially via the MEK/RTK-IGFBP2-RTK signaling loop. Here, KRAS is linked to non-small cell lung carcinoma.